BioCryst's RAPIVAB(TM) (peramivir injection) receives FDA approval for influenza
BioCryst announced the FDA has approved RAPIVAB (peramivir injection), an intravenous neuraminidase inhibitor for treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. December 22, 2014